Myriad Genetics, Inc. (Nasdaq: MYGN) announced that its BRACAnalysis CDx test accurately identified patients who may benefit from treatment ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Corporate News FDA Management Comments

AstraZeneca (AZN) Confirms FDA Partial Clinical Hold Placed on Patient Recruitment for MEDI4736 Trial in HNSCC; Issues CommentaryOctober 27, 2016 2:47 PM Myriad’s BRACAnalysis CDx® Test Identifies Patients with Ovarian Cancer Who Would Benefit from Second-Line Maintenance Treatment with OlaparibOctober 26, 2016 7:15 AM